Latest TB research highlights:
— BioVersys AG: BioVersys announces expansion of strategic collaboration with GSK
BioVersys AG announced the expansion of its strategic collaboration with GSK plc to accelerate the clinical development of alpibectir (BVL-GSK098) for the treatment of TB. Alpibectir, a small molecule acting through a novel mode of action, is currently being evaluated in combination with ethionamide in a Phase 2a proof-of-concept study in pulmonary TB patients in South Africa. The compound represents a totally new concept of overcoming resistance and significantly potentiating the activity of an existing antibiotic, ethionamide.
— Boston University: Who should receive preventive treatment for TB?
A study, published in The Lancet Respiratory Medicine, provided clarity on who should receive TB preventive treatment (TPT). Exposed individuals with confirmed TB infection — i.e. a positive skin or blood test — should receive priority TPT in settings with a low prevalence of the disease, regardless of their age. However, in high-burden settings, all exposed individuals should be considered for TPT, even without a confirmed infection.
— Harvard T.H. Chan School of Public Health: Age, sex may be important to consider in assessing TB risk
According to a study, published in Nature Microbiology, how an individual’s immune system responds to the bacteria that causes TB — and therefore whether they develop the disease — may differ across age and sex. “Our study is the first to examine whether we should be looking for different diagnostic markers in different groups of people — men versus women and kids versus adults, for example.”
— CIDRAP: TB-COVID co-infections increasingly common, tied to worse outcomes, data show
A meta-analysis of 17 studies, published in PLOS Neglected Tropical Diseases, revealed that TB and COVID-19 co-infection is becoming increasingly prevalent around the world, with death rates gradually declining but remaining higher than COVID-19 infection alone. The 17 studies were conducted in 38 countries or regions, spanning both high- and low-TB prevalence areas.
Check out the latest edition of the TB Online Weekly Newsletter (#15, 14 May 2024) for more TB research updates.
The TB Online Weekly Newsletter is brought to you by TB CAB and EATG. Subscribe to the newsletter here.
Related HIV and Co-Infections News
-
[Report] Physicians for Human Rights: Trump administration foreign policy approach to South Africa wastes billions of dollars, imperils global health
-
BMJ Group: Trial assesses safety and effectiveness of two new TB vaccines
-
AVAC: Abrupt shutdown of US global health supply chain raises risks for HIV, TB and malaria programs
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.